AU2012211301B2 - Compounds for the reduction of beta-amyloid production - Google Patents

Compounds for the reduction of beta-amyloid production Download PDF

Info

Publication number
AU2012211301B2
AU2012211301B2 AU2012211301A AU2012211301A AU2012211301B2 AU 2012211301 B2 AU2012211301 B2 AU 2012211301B2 AU 2012211301 A AU2012211301 A AU 2012211301A AU 2012211301 A AU2012211301 A AU 2012211301A AU 2012211301 B2 AU2012211301 B2 AU 2012211301B2
Authority
AU
Australia
Prior art keywords
mmol
dihydro
alkyl
cyclopenta
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012211301A
Other languages
English (en)
Other versions
AU2012211301A1 (en
Inventor
Kenneth M. Boy
Jason M. Guernon
John E. Macor
Richard E. Olson
Jianliang Shi
Lorin A. Thompson Iii
Yong-Jin Wu
Li Xu
Yunhui Zhang
Dmitry S. Zuev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2012211301A1 publication Critical patent/AU2012211301A1/en
Application granted granted Critical
Publication of AU2012211301B2 publication Critical patent/AU2012211301B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
AU2012211301A 2011-01-28 2012-01-26 Compounds for the reduction of beta-amyloid production Ceased AU2012211301B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161437279P 2011-01-28 2011-01-28
US61/437,279 2011-01-28
PCT/US2012/022665 WO2012103297A1 (en) 2011-01-28 2012-01-26 COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION

Publications (2)

Publication Number Publication Date
AU2012211301A1 AU2012211301A1 (en) 2013-09-19
AU2012211301B2 true AU2012211301B2 (en) 2016-02-25

Family

ID=45688981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012211301A Ceased AU2012211301B2 (en) 2011-01-28 2012-01-26 Compounds for the reduction of beta-amyloid production

Country Status (15)

Country Link
US (1) US8710061B2 (enExample)
EP (1) EP2668168B1 (enExample)
JP (1) JP5908499B2 (enExample)
KR (1) KR20140014152A (enExample)
CN (1) CN103328451B (enExample)
AR (1) AR084944A1 (enExample)
AU (1) AU2012211301B2 (enExample)
BR (1) BR112013018298A2 (enExample)
CA (1) CA2825906A1 (enExample)
EA (1) EA201391097A1 (enExample)
IL (1) IL226677A (enExample)
MX (1) MX2013008699A (enExample)
SG (1) SG191840A1 (enExample)
TW (1) TW201309655A (enExample)
WO (1) WO2012103297A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015025686B1 (pt) 2013-04-15 2020-10-27 Fmc Corporation composto, composições fungicidas e método para o controle das doenças dos vegetais
JP6688503B2 (ja) * 2014-11-21 2020-04-28 大学共同利用機関法人自然科学研究機構 医薬用組成物
EP3778605A3 (en) * 2015-02-13 2021-03-10 Dana Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
CN105017046A (zh) * 2015-07-15 2015-11-04 上海博康精细化工有限公司 一种4-环丙胺基丁酸乙酯的制备方法
MX379383B (es) * 2015-07-21 2025-03-10 Guangzhou Maxinovel Pharmaceuticals Co Ltd Compuesto de pirimidina de anillo fusionado, intermediario y método de preparación, composición y uso del mismo.
EP3717472B1 (en) * 2017-11-27 2022-07-27 F. Hoffmann-La Roche AG Pyrimidine derivatives
AU2020214064B2 (en) * 2019-01-29 2022-10-20 Shandong Xuanzhu Pharma Co., Ltd. Hexone glucokinase inhibitor and use thereof
CN112028839B (zh) * 2020-09-30 2022-04-12 中国海洋大学 一种医药中间体环烷烃并嘧啶二酮化合物的合成方法
TW202317528A (zh) * 2021-06-24 2023-05-01 美商富曼西公司 用於防治無脊椎有害生物的唑類化合物
CN117417302A (zh) * 2023-04-12 2024-01-19 江苏艾迪药业股份有限公司 艾诺韦林的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014535A1 (en) * 2009-07-31 2011-02-03 Bristol-Myers Squibb Company COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698627A1 (en) * 2000-09-15 2006-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP2226315A4 (en) * 2007-12-28 2012-01-25 Carna Biosciences Inc 2-aminoquinazoline DERIVATIVE
TW201030002A (en) * 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
US8637525B2 (en) * 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014535A1 (en) * 2009-07-31 2011-02-03 Bristol-Myers Squibb Company COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION

Also Published As

Publication number Publication date
US8710061B2 (en) 2014-04-29
CA2825906A1 (en) 2012-08-02
CN103328451B (zh) 2015-06-10
EP2668168A1 (en) 2013-12-04
IL226677A (en) 2014-11-30
TW201309655A (zh) 2013-03-01
BR112013018298A2 (pt) 2016-11-16
SG191840A1 (en) 2013-08-30
JP5908499B2 (ja) 2016-04-26
CN103328451A (zh) 2013-09-25
US20130030011A1 (en) 2013-01-31
AR084944A1 (es) 2013-07-10
JP2014503590A (ja) 2014-02-13
KR20140014152A (ko) 2014-02-05
MX2013008699A (es) 2013-08-21
EP2668168B1 (en) 2017-03-01
WO2012103297A1 (en) 2012-08-02
EA201391097A1 (ru) 2013-11-29
AU2012211301A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
AU2010279019B2 (en) Compounds for the reduction of beta-amyloid production
US8637525B2 (en) Compounds for the reduction of beta-amyloid production
US8710061B2 (en) Compounds for the reduction of β-amyloid production
CN114423756B (zh) 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
US10258626B2 (en) Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
JP5781066B2 (ja) ｐ１１０δに対して選択的な二環式ピリミジンＰＩ３Ｋ阻害剤化合物及び使用方法
CN105330698B (zh) 螺环芳基磷氧化物和硫化物
KR20130041944A (ko) 베타-아밀로이드 생성의 감소를 위한 화합물
KR20120052343A (ko) 융합된 아미노디하이드로피리미돈 유도체
EP3038466A1 (en) 2,2-difluorodioxolo a2a receptor antagonists
US20180118751A1 (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
TW201936614A (zh) 作為胞內體類鐸（toll-like）受體抑制劑之化合物及組合物
HK1164732B (en) Compounds for the reduction of beta-amyloid production

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired